Asset Details
Do you wish to reserve the book?
Inability of Plasma and Urine F2A-Isoprostane Levels to Differentiate Mild Cognitive Impairment from Alzheimer’s Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Inability of Plasma and Urine F2A-Isoprostane Levels to Differentiate Mild Cognitive Impairment from Alzheimer’s Disease
Do you wish to request the book?
Inability of Plasma and Urine F2A-Isoprostane Levels to Differentiate Mild Cognitive Impairment from Alzheimer’s Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Inability of Plasma and Urine F2A-Isoprostane Levels to Differentiate Mild Cognitive Impairment from Alzheimer’s Disease
2010
Overview
Background: Oxidative stress has been implicated in the pathogenesis of Alzheimer’s disease (AD). The pathobiological changes related to AD occur long before the overt clinical symptoms. The plasma lipid peroxidation enzyme F2-isoprostane has been suggested as a biomarker to detect the progression from mild cognitive impairment (MCI) to AD. Objective: To test whether plasma and urine F2-isoprostane was diagnostic for dementia in living people. Methods: Plasma and urine were collected from 222 Religious Orders Study participants with a clinical diagnosis of no cognitive impairment, MCI or AD at time of fluid collection. Isoprostane levels were determined using gas chromatography/mass spectroscopy. Results: Plasma and urine F2-isoprostane levels did not differ between the three clinical groups. Postmortem neuropathologic diagnosis of subjects who died during the course of the study was not associated with baseline blood or plasma F2-isoprostane levels. Conclusions: In living people, plasma or urine isoprostane levels were not sensitive enough to discriminate between individuals with a clinical diagnosis of no cognitive impairment, MCI or AD.
Publisher
S. Karger AG
Subject
ISBN
9783805593588, 3805593589
